{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:35:00Z","timestamp":1768808100538,"version":"3.49.0"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We aimed to describe treatment patterns of chronic lymphocytic leukaemia (CLL) patients in routine practice settings, compare overall survival and time\u2010to\u2010next\u2010treatment among patients treated in different time periods (2005\u20102008, 2009\u20102013, 2014\u20102015), and explore associated factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study included adult CLL patients from the Finnish Hematology Registry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 124 and 64 CLL patients received first\u2010 and second\u2010line treatments, respectively. The use of first\u2010 and second\u2010line treatments with bendamustine\u2010rituximab (BR) increased, while chlorambucil\u2010based treatments decreased over time. Patients treated in more recent years showed a trend towards longer first\u2010 and second\u2010line survival. A trend towards inferior overall survival was detected in first\u2010 and second\u2010line treatment with B\/BR. First\u2010line time\u2010to\u2010next\u2010treatment was longer for patients treated in the later years towards 2015, while second\u2010line time\u2010to\u2010next\u2010treatment did not improve over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study identified that improved treatment outcomes over time were likely influenced by patient characteristics and treatments, but also through other factors unexplored in this study. Hence, further research on the factors influencing patients\u2019 survival over time is needed. In particular, research on using B\/BR in clinical practice is warranted.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13273","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T09:19:32Z","timestamp":1560849572000},"page":"190-199","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL)\u00a0in Finland between 2005\u20102015 show improved survival over time"],"prefix":"10.1111","volume":"103","author":[{"given":"Vesa","family":"Lindstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Hematology Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki Helsinki Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja M.","family":"Hakkarainen","sequence":"additional","affiliation":[{"name":"StatFinn &amp; EPID Research Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juha","family":"Meht\u00e4l\u00e4","sequence":"additional","affiliation":[{"name":"StatFinn &amp; EPID Research Espoo Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riho","family":"Klement","sequence":"additional","affiliation":[{"name":"StatFinn &amp; EPID Research Tartu Estonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Leval","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag Ab Solna Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8646-314X","authenticated-orcid":false,"given":"Tiina M.","family":"J\u00e4rvinen","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag Oy Espoo Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30232-6"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.849"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0257-2"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-129379"},{"key":"e_1_2_8_6_1","unstructured":"Cancer statistics [Internet].Sy\u00f6p\u00e4rekisteri.https:\/\/cancerregistry.fi\/statistics\/cancer-statistics\/. Accessed May 29 2018."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0037-8"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24826"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv303"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12067"},{"key":"e_1_2_8_11_1","unstructured":"Finnish Association of Hematology.KLL hoito [Internet].https:\/\/www.hematology.fi\/fi\/hoito-ohjeet\/veritaudit\/kll\/hoito. Accessed June 6 2018."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2139"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.007849"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062930"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.105"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1246727"},{"key":"e_1_2_8_17_1","unstructured":"The Finnish Hematology Registry [Internet].http:\/\/www.fhrb.fi\/information-for-hospitals\/the-finnish-hematology-registry.html. Accessed May 28 2018."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"issue":"1","key":"e_1_2_8_19_1","first-page":"1744","article-title":"Outcome of patients with chronic lymphocytic leukemia (CLL) receiving first line therapy: a Swedish Nation\u2010Wide Study on 1053 consecutive patients treated between 2007 and 2013","volume":"130","author":"Sylvan SE","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_20_1","unstructured":"National Comprehensive Cancer Network\u00ae (NCCN\u00ae).NCCN Guidelines Version 1.2019: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. National Comprehensive Cancer Network\u00ae (NCCN\u00ae).2018."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.8061"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00465-9"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0276-9"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.189837"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.096792"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.01.023"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1259-3"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.07.004"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13129"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13273","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T18:39:41Z","timestamp":1692988781000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/ejh.13273"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13273","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,25]]},"assertion":[{"value":"2019-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}